Cargando…
Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354154/ https://www.ncbi.nlm.nih.gov/pubmed/32676346 http://dx.doi.org/10.21037/tlcr.2020.04.12 |
| _version_ | 1783558026212409344 |
|---|---|
| author | Yellala, Amulya Ganti, Apar Kishor |
| author_facet | Yellala, Amulya Ganti, Apar Kishor |
| author_sort | Yellala, Amulya |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7354154 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73541542020-07-15 Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) Yellala, Amulya Ganti, Apar Kishor Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2020-06 /pmc/articles/PMC7354154/ /pubmed/32676346 http://dx.doi.org/10.21037/tlcr.2020.04.12 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Yellala, Amulya Ganti, Apar Kishor Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title | Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title_full | Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title_fullStr | Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title_full_unstemmed | Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title_short | Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC) |
| title_sort | pembrolizumab—the “key” to an evolving landscape in treatment of squamous non-small cell lung cancer (nsclc) |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354154/ https://www.ncbi.nlm.nih.gov/pubmed/32676346 http://dx.doi.org/10.21037/tlcr.2020.04.12 |
| work_keys_str_mv | AT yellalaamulya pembrolizumabthekeytoanevolvinglandscapeintreatmentofsquamousnonsmallcelllungcancernsclc AT gantiaparkishor pembrolizumabthekeytoanevolvinglandscapeintreatmentofsquamousnonsmallcelllungcancernsclc |